American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

$LIFECORE BIOMEDICAL, INC. \DE\ logo$

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

$4.33 -2.26% NASDAQ: LFCR · 15-min delayed

CHASKA, Minnesota
Public · NASDAQ: LFCR
382 employees

Visit website Follow

$211.2MMarket cap

$557.6MRevenue · FY2019

-$38.7MNet income

382Employees

LFCRNASDAQ

1996IPO

About LIFECORE BIOMEDICAL, INC. \DE\

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: LFCR
Employees: 382
IPO date: Feb 15, 1996
Headquarters: 3515 LYMAN BOULEVARD
CHASKA, Minnesota 55318
Phone: (952) 368-4300
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: LFCR Nasdaq
SEC CIK: 1005286
EIN: 943025618
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Embed this company’s badge

Show Lifecore Biomedical, Inc. \de\’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/lifecore-biomedical-inc-de/"><img src="https://americancompanies.com/badge/lifecore-biomedical-inc-de.svg" alt="Lifecore Biomedical, Inc. \de\ — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow LIFECORE BIOMEDICAL, INC. \DE\ and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2019: $557.6M
Net income: -$38.7M
Total assets: $239.3M
Market cap: $211.2M
Gross margin: 31.3%
Operating margin: -13.4%
Net margin: -30.0%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $128.9M
Cost of revenue: $88.6M
Gross profit: $40.3M
Operating expenses: $57.5M
Operating income: -$17.2M
Income tax: $43.0K
Net income: -$38.7M
EPS (basic): $-1.27
EPS (diluted): $-1.27

Balance sheet

Total assets: $239.3M
Current assets: $85.7M
Total liabilities: $191.9M
Current liabilities: $30.2M
Shareholders’ equity: $1.3M

Cash flow

Operating cash flow: -$206.0K
Investing cash flow: -$6.4M
Financing cash flow: $6.4M
Net cash flow: -$197.0K

Statements via Polygon.io (SEC filings)

NASDAQ: LFCR

$4.33 -2.26%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$3.66 $8.82

52-week range

Market cap: $211.2M
EPS (diluted): $-1.27
Shares outstanding: 48.8M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Feb 15, 1996

Lifecore Biomedical, Inc. \de\ (LFCR) Stock Price

Reported a net loss of $38.7M in FY2019.
Revenue grew 25% from FY2023 to FY2025.
Gross margin of 31.3%, net margin -30.0%.
Trading 51% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review LIFECORE BIOMEDICAL, INC. \DE\.

Write a review

Newsroom

News about LIFECORE BIOMEDICAL, INC. \DE\

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCR GlobeNewswire Inc. · 2026-04-06 · negative Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company GlobeNewswire Inc. · 2026-03-23 · positive Green Dot Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses GlobeNewswire Inc. · 2026-03-17 · negative Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses GlobeNewswire Inc. · 2026-03-16 · negative Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. · 2026-01-16 · neutral Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer GlobeNewswire Inc. · 2025-12-17 · positive

News & sentiment via Polygon.io

FAQ

Lifecore Biomedical, Inc. \de\: frequently asked questions

Is Lifecore Biomedical, Inc. \de\ an American company?

Lifecore Biomedical, Inc. \de\ is a US-based company headquartered in Chaska, Minnesota, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Lifecore Biomedical, Inc. \de\ headquartered?

Lifecore Biomedical, Inc. \de\ is headquartered in Chaska, Minnesota, United States.

Is Lifecore Biomedical, Inc. \de\ publicly traded?

Yes — Lifecore Biomedical, Inc. \de\ is a publicly traded company. Its stock trades under the ticker symbol LFCR on the NASDAQ.

What does Lifecore Biomedical, Inc. \de\ do?

Lifecore Biomedical, Inc. \de\ is an American Pharmaceuticals company in the Health & Beauty sector.

Explore